The STD - Comprehensive panel contains 4 tests with 12 biomarkers.
Brief Description: The STD Comprehensive panel offers a broad overview of an individual's sexual health by screening for several prevalent sexually transmitted diseases. This comprehensive approach ensures that both bacterial and viral infections are tested for, providing a detailed picture of potential risks and existing infections, many of which may be asymptomatic.
Collection Method: Blood Draw and Urine Collection
Specimen Type: Blood Serum and Urine
Test Preparation: Urine specimens: The patient should not have urinated for at least one hour prior to specimen collection. Female patients should not cleanse the labial area prior to providing the specimen.
Hepatitis B Surface Antigen with Reflex Confirmation: Positive samples will be confirmed based on the manufacturer's FDA approved recommendations at an additional charge (CPT code(s): 87341).
If Hepatitis C Antibody is reactive, Hepatitis C Viral RNA, Quantitative, Real-Time PCR will be performed at an additional charge (CPT code(s): 87522).
When and Why the STD Comprehensive Panel May Be Ordered
The STD Comprehensive panel is often ordered for individuals who are sexually active, especially if they have multiple partners, are entering a new relationship, or have been recently exposed to an STD. It's also crucial for those showing symptoms of an STD or for individuals whose partners have been diagnosed with an STD. This panel is essential not only for diagnostic purposes but also for routine screening to ensure early detection, intervention, and to minimize transmission risks.
What the STD Comprehensive Panel Checks For
Chlamydia/Neisseria gonorrhea RNA, TMA: Using transcription-mediated amplification, this test detects the RNA of the bacteria causing chlamydia and gonorrhea. These are common bacterial STDs which can have serious health repercussions if not addressed.
Hepatitis A Antibody Total: This test detects antibodies produced in response to the Hepatitis A virus. The presence of these antibodies indicates either a past or current infection.
Hepatitis B Surface Antibody Qualitative: This test measures the antibodies produced after exposure to the Hepatitis B virus, indicating immunity either from past infection or vaccination.
Hepatitis B Core Antibody Total: This test identifies antibodies against the core antigen of the Hepatitis B virus, indicating either a past or ongoing infection.
Hepatitis B Surface Antigen with Reflex to Confirmation: It detects the surface antigen of the Hepatitis B virus, indicating a current infection. A reflex to confirmation ensures accurate results.
Hepatitis C Antibody with Reflex to HCV, RNA Quantitative Real-Time PCR: Initial screening for antibodies against the Hepatitis C virus. If positive, a reflex test quantifies the amount of virus in the blood.
Herpes Simplex Virus 1/2 IgG Type Specific Antibodies: This test differentiates between HSV-1 (usually oral herpes) and HSV-2 (usually genital herpes) by identifying the specific antibodies against each.
RPR with Reflex to Titer: This is a screening test for syphilis. If reactive, a "reflex to titer" quantifies the amount of reagin in the blood, providing insights into the disease's activity.
How Healthcare Professionals Use the STD Comprehensive Panel Results
A healthcare professional uses the results of the STD Comprehensive panel to diagnose potential sexually transmitted infections. Positive results would lead to a recommended course of treatment—antibiotics for bacterial infections and antivirals for viral infections like herpes. For conditions like Hepatitis, early detection is crucial as it can lead to serious liver complications if left untreated. The results also guide professionals in advising patients on transmission prevention, potential complications, and the need to notify and test sexual partners.
Maintaining one's sexual health is a shared responsibility. The STD Comprehensive panel is an instrumental tool in identifying potential threats to an individual's health and the health of their partners. Regular screening, especially with comprehensive panels, ensures timely interventions and plays a pivotal role in the broader aim of reducing the spread of these infections in the community.
A positive RPR screen must be followed by a specific treponemal antibody test (e.g., FTA-ABS):
A positive result on the second method confirms the screening result and the affected person is diagnosed with syphilis.
A negative result on the treponemal test may mean that the initial RPR test was falsely positive. Further testing and investigation may be done to determine the cause of the false positive.
False-positive results have been associated in patients with infections, pregnancy, autoimmune disease, old age, Gaucher disease, and malignancy.
We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.